# Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

> **NCT04655365** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CHU de Quebec-Universite Laval** · enrollment: 50 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide capsule

## Key facts

- **NCT ID:** NCT04655365
- **Lead sponsor:** CHU de Quebec-Universite Laval
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-22
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655365, "Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04655365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*